Cell News and Research

RSS

Provectus' Phase 2 clinical trial of PV-10 for metastatic melanoma complete

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed the treatment portion, including all protocol-allowed retreatments of all patients, of its Phase 2 clinical trial of PV-10 for metastatic melanoma. The study involved treatment of 80 subjects with Stage III or Stage IV metastatic melanoma.

21 Sep 2009

Nasdaq issues noncompliance letter ThermoGenesis

ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products for processing and storing adult stem cells, said today it had received a letter dated September 16, 2009, indicating the Company had become non-compliant with the Nasdaq Capital Markets' minimum bid pricing requirement under rule 5550(a)(2) as the Company's closing bid price for the past 30 days had failed to meet the minimum bid of $1.00 per share.

21 Sep 2009

New study reveals that large abdominal fat cells contribute to type 2 diabetes in women

Middle-aged women with large abdominal fat cells have a higher risk of developing type 2 diabetes later in life compared to women with smaller fat cells. Waist circumference divided by body height can also be used to determine which women are at risk. This is shown in a new study from the Sahlgrenska Academy at the University of Gothenburg, Sweden.

21 Sep 2009

MDC scientist receives 1 million euros for diabetic research

A European Research Council (ERC) Starting Grant worth more than a million euros over the next five years has been awarded to Dr. Francesca M. Spagnoli of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch, Germany.

21 Sep 2009

Nanoviricides and Southern Research sign agreement to test anti-Influenza and anti-HIV drug candidates

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), reported today that it has signed a “Master Service Agreement” with the Southern Research Institute (“Southern Research”), Birmingham, AL. Southern Research is a well established, prestigious institution that has performed preclinical testing services for several vaccines and antivirals.

21 Sep 2009

Geron and Corning develop synthetic surface that supports the growth and differentiation of hESCs

Corning Incorporated (NYSE: GLW) and Geron Corporation (Nasdaq: GERN) today announced the successful development of novel synthetic surface matrices demonstrated to enhance and support the scalable manufacturing and growth of human embryonic stem cells (hESCs).

21 Sep 2009

Chronic viruses found living in prostate tumors

According to Dr. Ila R. Singh, an associate professor of pathology at the University of Utah, "for the first time we have analyzed prostate cancer and normal prostate tissue and found cancers are much more likely to have [the XMRV virus] ... It was also more likely to be present in more aggressive tumors," Singh said. "We found it in 20 percent of the least aggressive tumors and over 45 percent of the most aggressive tumors."

21 Sep 2009

Cyntellect releases new cell cytometry system

Cyntellect, Inc., a privately-held life sciences company commercializing products to advance life science and stem cell research, biopharmaceutical production, and drug discovery, today unveiled its Celigo™ adherent cell cytometry system, the Company’s new platform for non-invasive in situ live cell imaging.

21 Sep 2009

FDA approves Neuralstem's IND for commencing a stem cell trial to treat Amyotrophic Lateral Sclerosis

Neuralstem, Inc. (NYSE Amex: CUR) today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to commence a Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells.

21 Sep 2009

U.S. Department of Health & Human Services requests BioCryst for proposal for peramivir supply

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has received a request for proposal (RFP) from the U.S. Department of Health & Human Services (HHS) for the supply of intravenous (i.v) peramivir for the treatment of critically ill influenza patients under Emergency Use Authorization (EUA).

21 Sep 2009

Swedish researcher to receive Fernström Foundation's Nordic Prize

Internationally renowned Swedish researcher Professor Jan-Åke Gustafsson, from KI and the University of Houston, is this year's recipient of the Fernström Foundation's Nordic Prize. The prize, which is worth SEK 1 million, is one of Scandinavia's most prestigious medical prizes.

21 Sep 2009

HHS awards $77.2 million contract to BioCryst to complete Phase 3 development of peramivir

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has been awarded a $77.2 million contract modification by the U.S. Department of Health & Human Services (HHS) to complete Phase 3 development of its influenza neuraminidase inhibitor, intravenous (i.v.) peramivir, for the treatment of complicated influenza.

21 Sep 2009

Phase 1 clinical trial results evaluating ARIAD's investigational mTOR inhibitor ridaforolimus

ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced data from a Phase 1 clinical trial evaluating oral ridaforolimus, its investigational mTOR inhibitor, in combination with bevacizumab (Avastin®) in heavily pretreated patients with refractory metastatic solid tumors. The data were presented at the Joint Multidisciplinary Congress of the 15th annual European Cancer Organization (ECCO) and the 34th annual European Society of Medical Oncology (ESMO) taking place in Berlin, Germany.

21 Sep 2009

Study reveals that patients with NSCLC who received maintenance therapy with ALIMTA showed survival benefit

Data published today in The Lancet showed a survival benefit in nonsquamous patients with advanced non-small cell lung cancer (NSCLC) who received maintenance therapy with ALIMTA(R) (pemetrexed for injection) plus best supportive care as compared to placebo plus best supportive care.

21 Sep 2009

NIAID awards DOR BioPharma a $9M grant to develop thermostable and rapidly acting vaccines

DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biotechnology company, announced today that it has been awarded an approximate $9.4 Million grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH).

21 Sep 2009

The 2009 National Pharmacy Study ranks Prescription Solutions second among mail order pharmacies

Prescription Solutions, a leading pharmacy benefits management (PBM) organization and a UnitedHealth Group (NYSE:UNH) company, today announced that it received the highest rankings for customer service and cost competitiveness factors among mail order pharmacies in the J.D. Power and Associates 2009 National Pharmacy StudySM.

21 Sep 2009

Amgen announces results of Phase 3 trial in the treatment of bone metastases

Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3 trial evaluating denosumab administered subcutaneously versus Zometa(R) (zoledronic acid) administered as an intravenous infusion in the treatment of bone metastases in 1,776 advanced cancer patients with solid tumors (not including breast and prostate cancer) or multiple myeloma. These results were presented today at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany (Abstract Number: 20LBA).

21 Sep 2009

Differences between two types of integrins

The adhesion of cells to the various components of their environment is mediated mainly by molecules known as integrins. Two integrins, α5β1 and αvβ3, mediate adhesion with fibronectin, which is present in the extracellular matrix. But why are 2 molecules involved in the adhesion to a single extracellular component? An article published on-line in Proceedings of the National Academy of Sciences (PNAS), whose main author is Pere Roca-Cusachs, an IBEC researcher, offers the first experimental answer to this question.

21 Sep 2009

Identification of nitric oxide using lasers and sensors

Nitric oxide, a gas well known to scientists for its myriad functions, has proven challenging to measure accurately outside the laboratory. A team of Princeton and Rice University researchers has demonstrated a new method of identifying the gas using lasers and sensors that are inexpensive, compact and highly sensitive. Such a portable device, suitable for large-scale deployment, could be of great value to atmospheric science, pollution control, biology and medicine.

21 Sep 2009

Bioniche Life Sciences' revenue increases by 21% for the fiscal year 2009

Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its 2009 fiscal year ended June 30, 2009.

21 Sep 2009

Cell News and Research

Provectus' Phase 2 clinical trial of PV-10 for metastatic melanoma complete

Nasdaq issues noncompliance letter ThermoGenesis

New study reveals that large abdominal fat cells contribute to type 2 diabetes in women

MDC scientist receives 1 million euros for diabetic research

Nanoviricides and Southern Research sign agreement to test anti-Influenza and anti-HIV drug candidates

Geron and Corning develop synthetic surface that supports the growth and differentiation of hESCs

Chronic viruses found living in prostate tumors

Cyntellect releases new cell cytometry system

FDA approves Neuralstem's IND for commencing a stem cell trial to treat Amyotrophic Lateral Sclerosis

U.S. Department of Health & Human Services requests BioCryst for proposal for peramivir supply

Swedish researcher to receive Fernström Foundation's Nordic Prize

HHS awards $77.2 million contract to BioCryst to complete Phase 3 development of peramivir

Phase 1 clinical trial results evaluating ARIAD's investigational mTOR inhibitor ridaforolimus

Study reveals that patients with NSCLC who received maintenance therapy with ALIMTA showed survival benefit

NIAID awards DOR BioPharma a $9M grant to develop thermostable and rapidly acting vaccines

The 2009 National Pharmacy Study ranks Prescription Solutions second among mail order pharmacies

Amgen announces results of Phase 3 trial in the treatment of bone metastases

Differences between two types of integrins

Identification of nitric oxide using lasers and sensors

Bioniche Life Sciences' revenue increases by 21% for the fiscal year 2009

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News